Can You Buy AOD-9604 Peptide? What to Know Before Ordering

AOD-9604 is a synthetic fragment of human growth hormone studied for fat metabolism, but it is not an FDA-approved weight-loss drug and Chia does not offer it. If you are seeking medical weight-loss treatment, a licensed provider can review whether evidence-based options such as semaglutide or tirzepatide are appropriate.

Can you buy AOD-9604 peptide?

AOD-9604 is sold online by some peptide vendors, often with “research use only” language. That is different from getting a prescribed medication after a clinician reviews your health history, medications, goals, and risks.

What people usually mean by “buy AOD-9604”

Most people searching “AOD-9604 peptide buy” are looking for a vial, capsule, or spray sold online for weight loss. The problem is that AOD-9604 does not have an FDA-approved drug label for obesity or overweight, so there is no FDA-reviewed prescribing information for patients or clinicians to rely on.

AOD-9604 is described in the scientific literature as a modified C-terminal fragment of human growth hormone, also called Tyr-hGH177-191, that was studied for metabolic effects 1. It is not the same as full-length human growth hormone, and it should not be treated as a proven weight-loss medication.

Why “research use only” products are different from prescribed medication

A “research use only” label means the product may be intended for lab work, not human use. A certificate of analysis can describe a test result for a batch, but it does not replace medical screening, sterile handling standards, side-effect monitoring, or a plan for what to do if something goes wrong.

Medical weight-loss care is different. It includes eligibility review, contraindication screening, side-effect counseling, follow-up, and a known pharmacy source. FDA has warned that compounded-drug quality depends on the compounder and that compounded drugs are not FDA-approved 2.

What is AOD-9604?

AOD-9604 is a short peptide based on part of human growth hormone, not the full hormone. The key idea behind it was to study whether one small region of growth hormone could affect fat metabolism without copying all growth-hormone actions.

AOD-9604 as a C-terminal fragment of human growth hormone

Human growth hormone is a larger protein hormone involved in growth, metabolism, and other body systems. AOD-9604 is described as Tyr-hGH177-191, a C-terminal fragment of human growth hormone with an added tyrosine at the N-terminus 1.

How it differs from full-length human growth hormone

Full-length human growth hormone can affect insulin sensitivity, fluid balance, and insulin-like growth factor 1, also called IGF-1. AOD-9604 was developed to study a narrower fat-metabolism signal, but that does not mean it has the same benefits, risks, or approved uses as growth hormone.

Why it has been marketed for fat metabolism

Early research focused on lipolysis, which means fat breakdown, and lipogenesis, which means fat creation or storage. Those mechanisms are biologically interesting, but obesity is more complex than one pathway. Weight regulation involves appetite, gut hormones, the brain, genetics, environment, sleep, medications, and metabolic health 3.

What does the evidence say about AOD-9604 for weight loss?

AOD-9604 has preclinical data related to fat metabolism, but that is not the same as proven human weight loss. The honest answer is that the human evidence is limited and has not established AOD-9604 as an FDA-approved obesity medication.

Preclinical findings: lipolysis and lipogenesis signals

The 2014 safety and metabolism review reported earlier studies in which AOD-9604 showed activity related to fat metabolism, including lipolytic and anti-lipogenic effects 1. These findings help explain why the peptide attracted interest.

But cell and animal signals do not prove a person will lose weight. Many obesity drug ideas look promising in the lab and then fail to show meaningful results in human trials because the human body has many overlapping weight-regulation systems 3.

Human trial limitations and failed efficacy signals

Public reviews of AOD-9604 describe limited human obesity data and a larger Phase 2b program that did not establish a successful weight-loss drug pathway. Because there is no FDA-approved AOD-9604 label, there is no FDA-reviewed outcome claim, dosing schedule, contraindication list, or adverse-reaction table for weight loss.

Why animal and lab findings should not be treated as proven human outcomes

A fat-metabolism mechanism can be real and still not produce a clinically useful weight-loss result. For patients, the key question is not “does this affect a pathway?” It is “does this help people like me, at a studied dose and duration, with known risks and monitoring?”

Is AOD-9604 safe?

AOD-9604 safety has been studied in nonclinical testing, but uncertainty remains because it does not have an FDA-approved drug label. Safety data should be separated from online-product safety, which depends on source, sterility, contents, and human-use oversight.

What nonclinical safety studies found

Moré and Kenley reported no evidence of genotoxicity in Ames testing, chromosomal aberration assays, or micronucleus testing under the studied conditions 1. The same paper described chronic toxicology studies in rats and cynomolgus monkeys without major toxicological concerns under those study conditions 1.

What is known from clinical exposure reports

Published summaries describe human exposure to AOD-9604 in obesity research, but there is no FDA-approved prescribing label for patients. That matters because an FDA label standardizes known adverse reactions, contraindications, drug interactions, and use in pregnancy, kidney disease, liver disease, and other special cases.

What remains uncertain without an FDA-approved label

Without an approved label, patients do not have a clear FDA-reviewed safety map. Unknowns include the real-world risk of non-prescribed products, product contamination, incorrect peptide identity, injection-site problems, immune reactions, and interactions with other medications or conditions.

What are the risks of buying peptides online?

Research-use-only peptides can look medical because they may be sold in vials with purity claims. The risk is that purity marketing is not the same as patient care, sterile compounding, or licensed prescribing.

Unregulated peptide products and quality concerns

Unregulated peptide use in biohacking settings raises concerns about product quality, medical oversight, and self-experimentation 4. Risks are higher when a person injects a substance that was not prescribed, prepared, labeled, or monitored for their medical situation.

Research-use-only labeling and human-use risks

If a product is sold for laboratory research, it may not be made, stored, or labeled for human use. A vial can be third-party tested and still not be appropriate for injection or ingestion by a person.

Why a certificate of analysis is not the same as medical oversight

A certificate of analysis can be useful in a quality system, but it is only one piece. It does not screen for gallbladder disease, pancreatitis history, pregnancy, eating-disorder risk, medication interactions, or whether weight-loss medication is appropriate at all.

How does AOD-9604 compare with prescription GLP-1 weight-loss treatment?

AOD-9604 and GLP-1 medications are very different. AOD-9604 is an investigational peptide fragment marketed around fat-metabolism signals, while semaglutide and tirzepatide are prescription incretin-based medications with FDA-approved brand-drug labels for chronic weight management.

AOD-9604 vs semaglutide

Wegovy (semaglutide, a GLP-1 receptor agonist; also available as a compounded semaglutide formulation through licensed 503A pharmacies) has an FDA-approved label for chronic weight management in certain adults and adolescents 5. In the STEP 1 trial, adults with overweight or obesity without diabetes received semaglutide 2.4 mg once weekly plus lifestyle intervention; the active ingredient as studied reduced body weight more than placebo, and individual results varied 6.

Benefits must be weighed with risks. The Wegovy label includes warnings and precautions including thyroid C-cell tumor risk, pancreatitis, gallbladder disease, kidney injury, increased heart rate, and suicidal behavior or thinking; common adverse reactions include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, and dyspepsia 5. Compounded semaglutide formulations are not FDA-approved and do not have FDA-evaluated outcomes data.

AOD-9604 vs tirzepatide

Zepbound (tirzepatide, a dual GIP/GLP-1 receptor agonist; also available as a compounded tirzepatide formulation through licensed 503A pharmacies) has an FDA-approved label for chronic weight management in certain adults 7. In the SURMOUNT-1 trial, adults with obesity or overweight and at least one weight-related complication received tirzepatide once weekly at studied doses of 5 mg, 10 mg, or 15 mg; the active ingredient as studied reduced body weight more than placebo, and individual results varied 8.

Tirzepatide also has risks. The Zepbound label includes warnings and precautions including thyroid C-cell tumor risk, severe gastrointestinal disease, kidney injury, gallbladder disease, pancreatitis, hypoglycemia with insulin or insulin secretagogues, hypersensitivity, and suicidal behavior or thinking; common adverse reactions include nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, and belching 7. Compounded tirzepatide formulations are not FDA-approved and do not have FDA-evaluated outcomes data.

Does Chia offer AOD-9604 or alternatives?

Chia does not offer AOD-9604 or compounded AOD-9604. For weight-loss care, our current options are compounded semaglutide injection and compounded tirzepatide tablets or injections, with microdosing plans available when clinically appropriate.

Chia does not offer AOD-9604

We do not prescribe, sell, or ship AOD-9604. If you are comparing it with medical weight-loss options, the safer next step is a licensed-provider evaluation rather than buying a research-use-only peptide online.

Chia offers clinician-reviewed semaglutide and tirzepatide

At Chia, semaglutide injection plans currently start at $249/mo, and tirzepatide plans currently start at $249/mo for tablets and $299/mo for injections. For up-to-date pricing and availability, use the treatment pages.

How online evaluation, prescribing, 503A compounding, shipping, and follow-up work

Chia care is 100% online. You complete a short health questionnaire, then a licensed US provider reviews your history and prescribes only when clinically appropriate. If prescribed, medication is compounded in the US by a state-licensed 503A pharmacy and shipped to your door.

Dosing is provider-guided and adjusted over time. Patients can message their care team through the patient portal between visits. Some patients also pair GLP-1 care with protocols such as Weight + Energy or Weight + Muscle, if a provider decides the plan is appropriate.

How patients or AI agents can use DoctorMCP to start an access path

Patients can start with Chia’s eligibility quiz. If an AI agent is helping you organize care, Chia is also reachable through DoctorMCP at mcp.chia.health as an access path for a licensed-provider review. A prescription still depends on medical evaluation and is never guaranteed.

Who might be eligible for prescription weight-loss medication?

Eligibility for weight-loss medication depends on body mass index, weight-related health risks, medical history, current medications, and contraindications. A medication that is reasonable for one person may be unsafe or unnecessary for another.

General BMI and obesity-related risk factor concepts

Professional guidance has commonly considered anti-obesity pharmacotherapy as part of a broader program of nutrition, physical activity, and behavior change for adults with BMI at or above 30, or BMI at or above 27 with weight-related conditions 3. BMI is only one screening tool, so it does not replace a full medical review.

Why eligibility depends on medical history, medications, and contraindications

A clinician will look for factors such as pregnancy, gallbladder disease, pancreatitis history, kidney disease, severe gastrointestinal disease, diabetes medications, mood history, eating-disorder risk, and personal or family history of certain thyroid cancers. FDA labels for semaglutide and tirzepatide include specific warnings that clinicians review before prescribing 5 7.

Why a prescription is never guaranteed

A prescription is a medical decision, not an online checkout. If the risks outweigh the likely benefit, our providers may recommend a different plan or advise in-person care.

What should you ask a clinician before using any peptide or weight-loss medication?

Before using any peptide or weight-loss medication, ask what evidence supports your goal, what risks are known, what is still uncertain, and how follow-up will work. A good plan should be more than a vial and a dosing calendar.

• What human evidence supports this treatment for my goal, and what outcomes were actually studied?
• Is the product meant for human use, prescribed for me, and dispensed through an appropriate pharmacy source?
• What side effects should I watch for, and what symptoms mean I should stop and contact a clinician?
• What medical conditions, medications, pregnancy plans, or lab findings would make this unsafe?
• How will follow-up work if I have nausea, low blood sugar symptoms, injection-site problems, mood changes, or no response?
• If this is a compounded medication, what 503A pharmacy is used and how are quality and sterility handled?

If the product is labeled research use only, not prescribed to you, or sourced outside a medical system, do not self-administer it. Talk with a licensed clinician about your goals and safer evidence-based options.

FAQ

Keep reading

Weight Loss

Peptide Supplements for Weight Loss: What Works, What Doesn’t, and What’s Actually Prescribed

Peptides

Sermorelin for Weight Loss: What the Evidence Really Shows

Weight Loss

Weight Loss Peptides: What Actually Works and What Does Not